RxDoctor Payments Data

Patrick Anderson, MD

Gynecologic Oncology · South Orange, NJNPI 1376548925

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,550 of the $2,440 with a category attached, or 63.5%. 11 manufacturers reported payments, led by Intuitive Surgical at 57.7% of the total. Reporting peaked in 2023 at $1,748 and has fallen 80.5% since, to $341 in 2025.

$2,440in general payments, 2019–2025

Across 54 payments — averaging $45.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$1K
  • Merck$492
  • Dilon Technologies, Inc.$149
  • Baxter Healthcare$117
  • AstraZeneca$109
  • GSK$60
  • plus $104 from 5 others

What the payments were for

  • Travel & lodging$83634%
  • Food & beverage$1,55064%
  • Education$311%
  • Gifts$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,440 in reported general payments places this provider in the 75th percentile of 45 gynecologic oncology providers in New Jersey.

See all gynecologic oncology providers in New Jersey

Medicare billing

Part B allowed, 2024
$60,846
Medicare patients
117
Services billed
431

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LenvimaLenvatinib Mesylate23$549,806
EliquisApixaban27$14,915
Ibandronate Sodium146$4,792
Estradiol27$2,700
Fentanyl17$1,592
Ondansetron Hcl39$1,205
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst34$807
Dexamethasone45$737
Clobetasol Propionate15$729
ValacyclovirValacyclovir Hcl23$641
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl25$432
Gabapentin45$417
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen44$388
Oxycodone Hcl13$312
Prochlorperazine Maleate15$279

Paid to pharmacies, not to this prescriber.

Other gynecologic oncology in South Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →